However, the impact of diabetes on survival in patients treated with fibrinolyticagents is still undefined.
2
Attempts to improve thrombolytic treatment include the search for better fibrinolyticagents and more effective adjunctive therapies.
3
The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolyticagents.
4
Conclusions: A history of diabetes is associated with a worse prognosis after myocardial infarction, even in patients treated with fibrinolyticagents.
5
Methods: We analyzed prevalence and prognostic significance of a history of diabetes in patients enrolled in the GISSI-2 study, all of whom received fibrinolyticagents.
1
Current methods for enzymatic activity of thrombolyticdrugs are costly and complex.
2
Its efficacy is comparable to that of other available thrombolyticdrugs.
3
Early treatment with thrombolyticdrugs has been shown to reduce mortality in patients with acute myocardial infarction.
4
Thrombolyticdrugs (rt-PA followed by Streptokinase) were injected via the same filter catheter.
1
However, the impact of diabetes on survival in patients treated with fibrinolyticagents is still undefined.
2
Attempts to improve thrombolytic treatment include the search for better fibrinolyticagents and more effective adjunctive therapies.
3
The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolyticagents.
4
Conclusions: A history of diabetes is associated with a worse prognosis after myocardial infarction, even in patients treated with fibrinolyticagents.
5
Methods: We analyzed prevalence and prognostic significance of a history of diabetes in patients enrolled in the GISSI-2 study, all of whom received fibrinolyticagents.
Ús de thrombolytic agents en anglès
1
These findings indicated that AnxB1ScuPA might have advantages over current available thrombolyticagents.
2
However, thrombolyticagents have limited effectiveness and are associated with a significant risk of bleeding.
3
The newer-generation thrombolyticagents remain of limited efficacy in the treatment and prevention of shock.
4
Twelve randomized, controlled trials of thrombolyticagents in 611 UA patients with predefined clinical endpoints have been published.
5
This meta-analysis showed that thrombolyticagents significantly improved the rate of return of spontaneous circulation, 24 h surviva …
6
The SBP of patients who received thrombolyticagents was lower than that of those who did not receive this therapy.
7
These observations laid a solid foundation for further study on developing new thrombolyticagents with higher efficiency and lower side effect.
8
Current parenteral antithrombotic and thrombolyticagents used to treat these conditions are limited by a short therapeutic window, irreversibility, and major risk of hemorrhage.
9
Objective: To pool data on the role of thrombolyticagents in cardiopulmonary resuscitation (CPR) and evaluate the efficacy and safety of thrombolysis.
10
Background and purpose: Thrombolyticagents hold theoretical promise as therapy for cerebral infarction.
11
Conclusion: Thrombolyticagents during CPR can improve the survival rate to discharge and neurological function.